featured
Nivolumab Plus Chemotherapy vs Placebo Plus Chemotherapy in HER2-Negative, Untreated, Unresectable Advanced or Recurrent Gastric or GEJ Junction Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Lancet Oncol 2022 Jan 11;[EPub Ahead of Print], YK Kang, LT Chen, MH Ryu, DY Oh, SC Oh, HC Chung, KW Lee, T Omori, K Shitara, S Sakuramoto, IJ Chung, K Yamaguchi, K Kato, SJ Sym, S Kadowaki, K Tsuji, JS Chen, LY Bai, SY Oh, Y Choda, H Yasui, K Takeuchi, Y Hirashima, S Hagihara, N BokuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.